XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue Recognition - Nature of Goods and Services (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
agreement
Sep. 30, 2024
USD ($)
Dec. 31, 2024
Revenue Recognition [Line Items]          
Number of operating segments | segment     1    
Customers average payment term     30 days    
Distributors average payment term     60 days    
Number of distribution and license agreements | agreement     3    
Net revenue $ 15,927 $ 28,316 $ 50,912 $ 76,824  
Concentrate Products          
Revenue Recognition [Line Items]          
Net revenue 15,927 $ 28,305 50,587 $ 76,790  
Da Vita | Concentrate Products          
Revenue Recognition [Line Items]          
Net revenue $ 400   1,700    
Sun Pharma, Jeil Pharma, and Drogsan Pharma          
Revenue Recognition [Line Items]          
Deferred revenue     $ 300    
Da Vita | Revenue Benchmark | Customer Concentration Risk          
Revenue Recognition [Line Items]          
Customer concentration, percentage 12.00% 52.00% 17.00% 47.00%  
Da Vita | Accounts Receivable | Customer Concentration Risk          
Revenue Recognition [Line Items]          
Customer concentration, percentage     12.00%   20.00%
Customer | Revenue Benchmark | Customer Concentration Risk          
Revenue Recognition [Line Items]          
Customer concentration, percentage 11.00%   10.00%